Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis

•Reducing treatment burden is a high priority for people living with CF. •Standard of care involves the use of multiple nebulized therapies which are time consuming. •Prescription refills for nebulized dornase alfa and hypertonic saline decreased in the first year post-ETI. •Several ongoing studies are evaluating the safety of withdrawing nebulized therapies post-ETI.